Mesoblast (MESO) Income towards Parent Company (2014 - 2023)
Mesoblast (MESO) posted Income towards Parent Company of -$21.9 million for Q2 2023, down 17.84% sequentially from -$18.6 million in Q1 2023, and down 2.16% YoY from -$22.4 million in Q2 2022.
Mesoblast (MESO) Income towards Parent Company (2014 - 2023) Analysis & Trends
Mesoblast has reported Income towards Parent Company for 10 years, with the latest figure at -$21.9 million in Q2 2023.
- Quarterly Income towards Parent Company fell 2.16% year-over-year to -$21.9 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was -$21.9 million (up 66.28% YoY) and the FY2025 annual result came in at -$102.1 million, down 16.13% from the prior year.
- Income towards Parent Company eased to -$21.9 million in Q2 2023 per MESO's latest filing, from -$18.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$5.5 million in Q3 2019 and troughed at -$32.6 million in Q2 2020.
- A 5-year average of -$22.0 million and a median of -$22.4 million in 2021 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2019 and 2020: Income towards Parent Company jumped 71.87% in 2019, then tumbled 347.56% in 2020.
- Over 5 years, Income towards Parent Company stood at -$24.6 million in 2019, then fell by 4.51% to -$25.7 million in 2020, then dropped by 0.98% to -$25.9 million in 2021, then advanced by 5.62% to -$24.5 million in 2022, then increased by 10.48% to -$21.9 million in 2023.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$21.9 million, -$18.6 million, and -$24.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.92 Mn |
| Mar 31, 2023 | -18.60 Mn |
| Dec 31, 2022 | -24.49 Mn |
| Sep 30, 2022 | -16.88 Mn |
| Jun 30, 2022 | -21.46 Mn |
| Mar 31, 2022 | -21.30 Mn |
| Dec 31, 2021 | -25.95 Mn |
| Sep 30, 2021 | -22.65 Mn |
| Jun 30, 2021 | -22.06 Mn |
| Mar 31, 2021 | -26.52 Mn |
| Dec 31, 2020 | -25.69 Mn |
| Sep 30, 2020 | -24.54 Mn |
| Jun 30, 2020 | -32.61 Mn |
| Mar 31, 2020 | -15.26 Mn |
| Dec 31, 2019 | -24.58 Mn |
| Sep 30, 2019 | -5.48 Mn |
| Jun 30, 2019 | -20.73 Mn |
| Mar 31, 2019 | -24.97 Mn |
| Dec 31, 2018 | -24.60 Mn |
| Sep 30, 2018 | -19.50 Mn |